

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
9.0	20.06.2025	6199205-00016	Date of first issue: 24.08.2020

SECTION 1: IDENTIFICATION

Product name : Molnupiravir Capsule Formulation

Manufacturer or supplier's details

Company : MSD

Address : Building A - Level 1/26 Talavera Rd
Macquarie Park NSW, Australia 2113

Telephone : 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification**

Specific target organ toxicity - repeated exposure (Oral) : Category 1 (Gastrointestinal tract)

GHS label elements

Hazard pictograms	: 
Signal word	: Danger
Hazard statements	: H372 Causes damage to organs (Gastrointestinal tract) through prolonged or repeated exposure if swallowed.
Precautionary statements	: Prevention: P260 Do not breathe dust. P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product. Response: P314 Get medical advice/ attention if you feel unwell. Disposal: P501 Dispose of contents/ container to an approved waste disposal plant.

Molnupiravir Capsule Formulation

Version 9.0	Revision Date: 20.06.2025	SDS Number: 6199205-00016	Date of last issue: 14.04.2025 Date of first issue: 24.08.2020
----------------	------------------------------	------------------------------	---

II**Other hazards which do not result in classification**

May form explosive dust-air mixture during processing, handling or other means.
Dust contact with the eyes can lead to mechanical irritation.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 60 -<= 100
Molnupiravir	2492423-29-5	>= 60 -<= 100

SECTION 4. FIRST AID MEASURES

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	: In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Causes damage to organs through prolonged or repeated exposure if swallowed. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

II Specific hazards during fire- : Avoid generating dust; fine dust dispersed in air in sufficient

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
9.0	20.06.2025	6199205-00016	14.04.2025
			Date of first issue: 24.08.2020

- | | | |
|---|---|---|
| fighting | | concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : | Carbon oxides
Metal oxides |
| Specific extinguishing methods | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area. |
| Special protective equipment for firefighters | : | In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment. |
-

SECTION 6. ACCIDENTAL RELEASE MEASURES

- | | | |
|---|---|--|
| Personal precautions, protective equipment and emergency procedures | : | Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
| Environmental precautions | : | Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained. |
| Methods and materials for containment and cleaning up | : | Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements. |
-

SECTION 7. HANDLING AND STORAGE

- | | | |
|-------------------------|---|--|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | Use only with adequate ventilation. |
-

Molnupiravir Capsule Formulation

Version 9.0 Revision Date: 20.06.2025 SDS Number: 6199205-00016 Date of last issue: 14.04.2025
Date of first issue: 24.08.2020

- Advice on safe handling** : Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage** : Keep in properly labelled containers.
Store in accordance with the particular national regulations.
- Materials to avoid** : Do not store with the following product types:
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Components with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m ³	AU OEL
		TWA	10 mg/m ³	ACGIH
Molnupiravir	2492423-29-5	TWA	20 µg/m ³ (OEB 3)	Internal
		Wipe limit	200 µg/100cm ²	Internal

- Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
9.0	20.06.2025	6199205-00016	14.04.2025
			Date of first issue: 24.08.2020

Personal protective equipment

Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Colour	:	white to off-white
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
9.0	20.06.2025	6199205-00016	Date of first issue: 24.08.2020

Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes	:	Inhalation Skin contact
-----------------	---	----------------------------

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
9.0	20.06.2025	6199205-00016	Date of first issue: 24.08.2020

Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Cellulose:**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg

Molnupiravir:

Acute oral toxicity	:	LD0 (Rat): 2,000 mg/kg
		LD0 (Dog): 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:**Molnupiravir:**

Species	:	reconstructed human epidermis (RhE)
Method	:	EpiDerm
Result	:	Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Molnupiravir:**

Species	:	Bovine cornea
Result	:	No eye irritation
Method	:	Bovine cornea (BCOP)

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
9.0	20.06.2025	6199205-00016	Date of first issue: 24.08.2020

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**Cellulose:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative

Molnupiravir:

Genotoxicity in vitro	:	Test Type: Ames test Result: positive
		Test Type: Micronucleus test Test system: human lymphoblastoid cells Result: negative
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Rat Cell type: Bone marrow Application Route: Oral Result: negative
		Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Rat Cell type: Bone marrow Result: equivocal
		Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Transgenic rat Application Route: Oral Result: negative
Germ cell mutagenicity - Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
9.0	20.06.2025	6199205-00016	Date of first issue: 24.08.2020

Components:**Cellulose:**

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	72 weeks
Result	:	negative

Reproductive toxicity

Not classified based on available information.

Components:**Cellulose:**

Effects on fertility	:	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
----------------------	---	---

Effects on foetal development	:	Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative
-------------------------------	---	--

Molnupiravir:

Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: > 200 mg/kg body weight Symptoms: Effects on embryofoetal and postnatal development Result: No effects on fertility and early embryonic development were detected. Remarks: Not classified due to data which are conclusive although insufficient for classification.
-------------------------------	---	--

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs (Gastrointestinal tract) through prolonged or repeated exposure if swallowed.

Components:**Molnupiravir:**

Exposure routes	:	Oral
Target Organs	:	Gastrointestinal tract
Assessment	:	Causes damage to organs through prolonged or repeated exposure.

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
9.0	20.06.2025	6199205-00016	Date of first issue: 24.08.2020

Repeated dose toxicity**Components:****Cellulose:**

Species	: Rat
NOAEL	: $\geq 9,000$ mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

Molnupiravir:

Species	: Rat
LOAEL	: 2,000 mg/kg
Exposure time	: 7 d
Target Organs	: Stomach

Species	: Dog
LOAEL	: 300 mg/kg
Exposure time	: 7 d
Target Organs	: Gastrointestinal tract
Symptoms	: tachycardia, decreased activity, decrease in appetite, Diarrhoea, Vomiting

Species	: Rat
NOAEL	: 500 mg/kg
Exposure time	: 28 d

Species	: Dog
NOAEL	: 6 mg/kg
LOAEL	: 17 mg/kg
Exposure time	: 28 d
Target Organs	: Gastrointestinal tract
Symptoms	: decreased activity, Gastrointestinal tract damage, decrease in appetite

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Molnupiravir:**

General Information	: Symptoms: Headache, Gastrointestinal disturbance Remarks: The most common side effects are: Symptoms: Back pain
---------------------	---

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
9.0	20.06.2025	6199205-00016	Date of first issue: 24.08.2020

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Cellulose:**

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Molnupiravir:

Toxicity to algae/aquatic plants : EC10 (Raphidocelis subcapitata (freshwater green alga)): 89 mg/l
End point: Growth
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : EC10 (Pimephales promelas (fathead minnow)): 5.8 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : EC10 (Daphnia magna (Water flea)): > 8.8 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC10: 143.1 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition of activated sludge
Method: OECD Test Guideline 209

Ecotoxicology Assessment

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Persistence and degradability**Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

Molnupiravir:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 81 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
9.0	20.06.2025	6199205-00016	Date of first issue: 24.08.2020

Bioaccumulative potential**Components:****Molnupiravir:**

Partition coefficient: n-octanol/water	:	log Pow: -0.534 pH: 7
--	---	--------------------------

Mobility in soil**Components:****Molnupiravir:**

Distribution among environmental compartments	:	OECD Test Guideline 106 log Koc: 1.45
---	---	--

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Environmentally hazardous	:	no

IATA-DGR

UN/ID No.	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
9.0	20.06.2025	6199205-00016	Date of first issue: 24.08.2020

Packing instruction (passenger aircraft) : Not applicable

IMDG-Code

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
EmS Code : Not applicable
Marine pollutant : Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**ADG**

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Hazchem Code : Not applicable

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

Therapeutic Goods (Poisons Standard) Instrument : No poison schedule number allocated (Please use the original publication to check for specific uses, specific conditions or threshold limits that might apply for this chemical)

Prohibition/Licensing Requirements : There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
9.0	20.06.2025	6199205-00016	Date of first issue: 24.08.2020

SECTION 16: ANY OTHER RELEVANT INFORMATION**Further information**

Revision Date : 20.06.2025
Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
AU OEL : Australia. Workplace Exposure Standards for Airborne Contaminants.

ACGIH / TWA : 8-hour, time-weighted average
AU OEL / TWA : Exposure standard - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Molnupiravir Capsule Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
9.0	20.06.2025	6199205-00016	Date of first issue: 24.08.2020

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN